Evidence map›Paper›PMID 29390360›Full record

ArticleMedicine2017

Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma.

Hsing-Tao Kuo, Jenny Que, Li-Ching Lin, Ching-Chieh Yang, Lok-Beng Koay, Chia-Hui Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. A Phase II Study of Optimized Individualized Adaptive Radiotherapy for Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Role of palliative SBRT in barcelona clinic liver cancer-stage C hepatocellular carcinoma patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023
    Observational
  8. Article
  9. Tumors Are Evolutionary Island-Like Ecosystems.Genome biology and evolution · 2021
    Article
  10. Review
  11. Thermal Ablation versus SBRT in liver tumours: pros and cons.Medical oncology (Northwood, London, England) · 2020
    Review
  12. Observational
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hsing-Tao KuoDepartment of Radiation Oncology Department of Internal Medicine, Division of Hepatology, Chi Mei Medical Center Department of Hospital and Health Care Administration Department of Optometry, Chung Hwa University of Medical Technology Department of Senior Citizen Service Management, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.
Jenny Que
Li-Ching Lin
Ching-Chieh Yang
Lok-Beng Koay
Chia-Hui Lin

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stereotactic body radiation therapy (SBRT) for inoperable hepatocellular carcinoma (HCC) offers excellent local control rates. This study retrospectively analyzed the influence of different tumor size on treatment outcomes after SBRT.Between December 2008 and February 2014, 141 HCC patients were treated with Cyberknife SBRT. Patients were divided into 3 groups namely small tumors (≤4 cm), intermediate-sized (>4-<10 cm), and large (≥10 cm) tumors. Treatment outcomes, prognoses, and safety at each tumor size were compared and analyzed.A total of 52 patients with small tumors, 55 with intermediate tumors, and 34 patients with large tumors were retrospectively analyzed with a median follow-up of 16 months. Objective responses were achieved at 96.15%, 90.90%, and 76.47% for small, intermediate, and large tumors, respectively (P ≤ .0001) and the 3-year local control rates were 97.85%, 71.99%, and 82.14%, respectively (P = .0035). The 3-year overall survival rates were 50.26%, 45.29%, and 33.38% for small, intermediate, and large tumors, respectively (P = .3757). No significant differences were found in overall-survival, intra-hepatic recurrence free survival, disease-progression free survival, or distant metastasis-free survival.SBRT offers the best effective local control rate and response rate for small HCCs. However, tumor size did not significantly affect the overall survival rate, intra-hepatic recurrence free rate, or disease-progression free rate.

Indexed as

RadiosurgeryCarcinoma, HepatocellularFemaleHumansLiver NeoplasmsMaleMiddle AgedRetrospective StudiesTreatment OutcomeTumor Burden

Identifiers

PMID29390360
PMCPMC5815772

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.